In the clonidine shortage, which action is most appropriate?

In the clonidine shortage, which action is most appropriate?

• A. Switch to a different antihypertensive
• B. Supply clonidine 100mcg tablet with a tablet cutter explaining unlicensed use
• C. Wait for stock
• D. Advise patient to stop therapy

Answer: (B)

In a drug shortage, the aim is to keep the patient on their effective therapy while minimizing safety risks and unnecessary interruptions. For clonidine, continuing treatment is important because abrupt stopping can cause rebound hypertension and other symptoms. The best approach is to adapt within safety and regulatory boundaries to maintain that therapy. Providing a clonidine 100 mcg tablet and using a tablet cutter to split it, with a clear explanation that this is an unlicensed use of the dosage form, does exactly that: it preserves ongoing treatment when a licensed, exact-dose option isn’t available. The pharmacist can counsel the patient on how to split accurately, the expected effect of the dose, potential risks if splitting is done imprecisely, and when to report adverse effects or seek a prescriber review. This approach balances continuity of care with safety and transparency about deviations from standard labeling, and it is typically preferable to waiting for stock or stopping therapy. Switching to another antihypertensive or waiting for stock could compromise blood pressure control or delay needed therapy, and advising the patient to stop would be harmful.

In a drug shortage, the aim is to keep the patient on their effective therapy while minimizing safety risks and unnecessary interruptions. For clonidine, continuing treatment is important because abrupt stopping can cause rebound hypertension and other symptoms. The best approach is to adapt within safety and regulatory boundaries to maintain that therapy.

Providing a clonidine 100 mcg tablet and using a tablet cutter to split it, with a clear explanation that this is an unlicensed use of the dosage form, does exactly that: it preserves ongoing treatment when a licensed, exact-dose option isn’t available. The pharmacist can counsel the patient on how to split accurately, the expected effect of the dose, potential risks if splitting is done imprecisely, and when to report adverse effects or seek a prescriber review. This approach balances continuity of care with safety and transparency about deviations from standard labeling, and it is typically preferable to waiting for stock or stopping therapy.

Switching to another antihypertensive or waiting for stock could compromise blood pressure control or delay needed therapy, and advising the patient to stop would be harmful.